Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Complete title: ADVL1622, Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Research Study Number ADVL1622
Principal Investigator Julie Park, MD
Phase II

Research Study Description

This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "LOOK UP TRIAL AT NIH" link above. **

Other eligibility criteria may apply.

Research Study Number ADVL1622
Contact Julie Park, MD
Telephone 206/667-1212

Keywords: Central Nervous System (CNS); Kidney Cancer; Liver Cancer; Pediatric Cancers, Miscellaneous; Sarcoma; Solid Tumors; Thyroid Cancer; Wilms' Tumor; Urogenital Neoplasms; Urologic Neoplasms; Rhabdomyosarcoma; Sarcoma, Ewing; Neoplasms, Glandular and Epithelial; Neoplasms, Connective and Soft Tissue; Adenocarcinoma; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Digestive System Diseases; Carcinoma, Medullary; Nervous System Diseases; Carcinoma, Renal Cell; Sarcoma, Clear Cell; Hepatoblastoma

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials